Enbridge Inc. (ENB) Financials Nov 18, 2014, 9:38
Enbridge Inc. (ENB) Financials Nov 18, 2014, 9:38 a.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Enbridge Inc.
Fiscal year is January-December. All values CAD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 12.47B 15.13B 19.4B 25.19B 33.65B
Cost of Goods Sold (COGS) incl. D&A 9.61B 12.06B 15.79B 20.39B 28.14B
COGS excluding D&A 8.84B 11.19B 14.85B 19.16B 26.77B
Depreciation & Amortization Expense 764M 864M 937M 1.24B 1.37B
Depreciation 713M 795M 870M - 1.28B
Amortization of Intangibles 44M 60M 61M - 88M
Gross Income 2.86B 3.07B 3.61B 4.8B 5.5B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 1.43B 1.47B 1.73B 2.68B 2.93B
Research & Development 0 0 0 0 -
Other SG&A 1.43B 1.47B 1.73B 2.68B 2.93B
Other Operating Expense 0 0 0 0 362M
Unusual Expense (35M) (73M) (176M) 650M 1.25B
EBIT after Unusual Expense 35M 73M 176M (650M) (1.25B)
Non Operating Income/Expense 747M 225M (68M) 328M 332M
Non-Operating Interest Income 65M 42M 38M 27M 27M
Equity in Affiliates (Pretax) 198M 38M 336M - -
Interest Expense 568M 753M 738M 838M 1.04B
Gross Interest Expense 664M 819M 799M 1.05B 1.29B
Interest Capitalized 96M 66M 61M 216M 250M
Pretax Income 1.91B 1.23B 1.63B 991M 283M
Income Tax 306M 251M 568M 171M 123M
Income Tax - Current Domestic 49M (29M) 207M 130M (30M)
Income Tax - Current Foreign 39M 42M (54M) 38M 22M
Income Tax - Deferred Domestic 117M 134M 31M 160M 31M
Income Tax - Deferred Foreign 101M 104M 384M (157M) 100M
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 195M 330M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 1.6B 980M 1.06B 1.02B 490M
Minority Interest Expense 37M 10M 56M 229M (135M)
Net Income 1.56B 970M 1B 786M 625M
Extraordinaries & Discontinued Operations 0 0 0 (79M) 4M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 (79M) 4M
Net Income After Extraordinaries 1.56B 970M 1B 707M 629M
Preferred Dividends 7M 7M 13M 105M 183M
Net Income Available to Common 1.56B 963M 991M 681M 442M
EPS (Basic) 2.14 1.30 1.32 0.78 0.55
Basic Shares Outstanding 728M 740M 751M 772M 806M
EPS (Diluted) 2.13 1.29 1.30 0.77 0.55
Diluted Shares Outstanding 732M 748M 761M 785M 817M
EBITDA 2.19B 2.47B 2.82B 3.36B 3.59B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....
Continue Reading
The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...
Continue Reading
A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...
Continue Reading
Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...
Continue Reading
CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...
Continue Reading
Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...
Continue Reading
University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...
Continue Reading
PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...
Continue Reading
Top 5 Most Recently Viewed Articles
Capricor Therapeutics Faces Legal Scrutiny Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself at the center of a significant legal issue as investors come forth with claims of securities fraud. The Rosen Law Firm, a leader in investor rights, has highlighted an important opportunity for those who purchased Capricor's securities during a specified period. This legal...
Continue Reading
Revolutionizing Therapeutics with AI Technology Harbour BioMed, a renowned biopharmaceutical leader, has made significant advancements in the field of drug discovery. The company specializes in developing novel antibody therapeutics primarily targeted at immunology and oncology. Their latest innovation arrives with the launch of the first fully human Generative AI HCAb...
Continue Reading
Intuit Inc Sees Promising Growth in Premarket Trading Intuit Inc (NASDAQ: INTU) has experienced a significant rise in its shares during premarket trading sessions, primarily due to its impressive financial performance in the recent quarter. The company's earnings report has exceeded market expectations, showcasing its ability to thrive in a competitive landscape....
Continue Reading
HR Acuity Announces Innovative Partnership with Labor Relations Institute HR Acuity has joined forces with Labor Relations Institute Consulting Services (LRICS) to foster a new era of collaboration among labor relations professionals. This exciting initiative aims to extend support to the increasingly critical domain of labor relations, particularly as workplace dynamics...
Continue Reading
Subsea7 Engages in New Offshore Project In a significant development for Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY), the company has secured a pivotal contract with ConocoPhillips Skandinavia AS for conducting a front-end engineering and design (FEED) study. This contract pertains to the Previously Produced Fields (PPF) project offshore, which marks an exciting stride...
Continue Reading